Developer docs
API playgroundTry for free, no card

Search company profiles

b.fab

Full company profile

uuid000897s

Namestring
b.fab
Legal namestring
b.fab GmbH
Websiteurl
bfab.bio
Company typeenum
Private
Founded yearint
2018
Descriptiontext

b.fab GmbH is a privately-held German biotechnology startup founded in February 2018 by Dr. Frank Kensy, Dr. Arren Bar-Even (deceased 2020) and b.value AG, headquartered in Cologne with origins in Dortmund. The company operates a proprietary Formate Bioeconomy platform that combines electrochemistry with synthetic biology to convert industrial CO2 and renewable electricity into value-added biochemicals. In its first stage, CO2 is electrochemically reduced to formic acid; in the second stage, engineered microbial strains (formatotrophs) using the reductive glycine pathway (rGP) — first demonstrated in vivo in E. coli by co-founder Bar-Even — convert formate into proteins, amino acids, biopolymers, fatty acids and terpenes. The company's technology has been validated in peer-reviewed work, including >3 g/L mevalonate titers from CO2-derived formate published in Nature Communications.

b.fab commercializes its technology through two routes: (1) licensing of synthetic biology pathways in microbial hosts using formic acid or methanol as the sole carbon source, targeted at enterprise chemical and manufacturing customers, and (2) direct product sales of Sustein, a single-cell protein for aquaculture feed launched in 2024 that requires 14x less land than soy protein. The company is embedded in multiple EU-funded research consortia — eforfuel (2018), TRANSFORMATE (BMBF, 2020–2023), and ICO2NIC (€14M, January 2025, 11 partners) — and participates in accelerators including Hatch Blue CREST (2024) and Circular Valley (2021). Its primary customer segments are enterprise chemical manufacturers seeking carbon-negative biomanufacturing inputs and the aquaculture feed industry seeking sustainable protein alternatives.

As of late 2025, b.fab operates with 1–10 employees, has no disclosed revenue, and is preparing for pilot-scale biochemical production in 2026 via its OCOchem partnership. The company is almost entirely grant-funded rather than equity-backed, with key milestones ahead including scaling rGP-based bioproduction and translating Sustein from pilot to commercial aquaculture sales.

Short descriptiontext

b.fab is a German biotech startup that converts industrial CO2 and renewable electricity into biochemicals via its proprietary Formate Bioeconomy platform, licensing synthetic biology pathways to chemical manufacturers and selling Sustein single cell protein for aquaculture feed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersKöln, Germany
HQ citystring
Köln
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CO2 utilization, synthetic biology, biomanufacturing technology, carbon-negative chemicals, single cell protein
Industry1 code
PRIMARYEUAAAIAA
Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code1 code
  • Other Basic Organic Chemical Manufacturing32519
SIC code1 code
  • Industrial Organic Chemicals2860
Product category
Industrial Biotechnology / Biomanufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing
TypeLicensing Royalties
Description

b.fab licenses its synthetic biology pathways and biomanufacturing technology to manufacturing and chemical industry companies. They offer technology licences for use of synthetic pathways in microbial hosts utilizing formic or methanol as sole carbon source.

bfab.bio
2Product Sales (Future)
TypeHardware Sales
Description

Plans to commercialize products including Sustein, a single cell protein made from CO2-based formate for aquaculture feed applications.

bfab.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Sustain
Description

Single cell protein made from CO2-based formate for aquaculture feed applications. Made from CO2 and renewable electricity using a simple fermentation process requiring minimal land use (14x less than soy protein).

bfab.bio
Core offering1 text field

b.fab develops and licenses a proprietary Formate Bioeconomy Platform that combines electrochemical CO2 conversion with synthetic biology to produce value-added biochemicals (amino acids, biopolymers, fatty acids, terpenes, proteins) from CO2 and renewable electricity. The company also produces Sustein, a single-cell protein made from CO2-based formate for aquaculture feed, offering it alongside its technology licensing business to manufacturing and chemical industry customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Sustein requires 14x less land than soy protein
+1 more record
Product overview1 text field

b.fab is a biotechnology company offering a unified platform combining electrochemistry and synthetic biology to convert CO2 and renewable energy into biochemicals. The core offering is the Formate Bioeconomy Platform, which converts CO2 to formic acid and then uses engineered microbial strains to produce value-added products. The company commercializes its technology through two main routes: (1) direct product sales of Sustein, a single cell protein for aquaculture feed, and (2) technology licensing, offering licences for synthetic pathways in microbial hosts using formic acid or methanol as the sole carbon source. The technology has been demonstrated for amino acids, biopolymers (PHB), fatty acids, terpenes, and proteins. b.fab also engages in collaborative research projects (e.g., ICO2NIC, TRANSFORMATE, eforfuel) to advance and scale its platform.

Product and service2 records
1Sustein
CategorySingle Cell Protein / Aquaculture Feed
Description

Sustein is a single-cell protein produced from CO2-based formate via a simple fermentation process using engineered microbial strains. It serves as a sustainable protein ingredient for aquaculture feed applications and requires 14x less land than conventional soy protein.

2Technology Licence for Synthetic Pathway in Microbial Hosts Utilizing Formic or Methanol as Sole Carbon Source
CategoryTechnology Licensing / Biomanufacturing Platform
Description

b.fab offers technology licensing for synthetic biology pathways in microbial hosts that use formic acid or methanol as the sole carbon source. The technology has been demonstrated for amino acids, biopolymers, fatty acids, terpenes, and proteins, and can be tuned to customer-specific needs for chemical industry and manufacturing partners.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Partnership to accelerate production of biochemicals using OCOchem's sustainably made CO2-based formate. OCOchem has developed gas diffusion electrodes achieving 100x greater CO2 conversion, room temperature/pressure operation, and 35%+ formate concentration. Collaboration enables b.fab to scale technology using fossil-free formate and close the industrial CO2 circle. Small pilot scale production starting 2026.

2ICO2NIC Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

EU-funded project with €14 million in funding. 11 partners across CCU value chain including SINTEF, Avantium, Tüpraş, Cool Planet Technologies, Procter & Gamble, Idener, Nopalm Ingredients, Bio Base Europe Pilot Plant, TNO, and CO2 Value Europe. b.fab will scale up bioprocess for protein production and demonstrate value chain from industrial CO2 emitter to feed customers over 4 years starting January 2025.

bfab.bio
3TRANSFORMATE Project Partners
Strategic tierMajorTypeStrategic or Co-development Partner
Description

BMBF-funded project (01.03.2020 to 28.02.2023) with 7 partners: Max Planck Institute for Molecular Plant Physiology, Max Planck Institute for Colloids and Interfaces, University Stuttgart, Ertel IonStream UG, YNCORIS GmbH & Co. KG, and Dechema e.V. Goal: convert CO2 from industrial parks into biopolymers (PHB and crotonic acid) using electrochemical conversion and biotechnology.

bfab.bio
4eforfuel Project Consortium
Strategic tierMajorTypeStrategic or Co-development Partner
Description

4-year European project starting March 2018 coordinated by co-founder Arren Bar-Even. Goal: De novo metabolic conversion of electrochemically produced formate into hydrocarbon fuels.

bfab.bio
Strategic tierMajorTypeGTM or Marketing Partner
Description

World-leading aquaculture accelerator program. b.fab selected for intensive 4-month program across Hawai'i, Norway, Singapore and Vietnam to access global aquaculture industry, receive mentorship, and develop business plan with deliverables including Life Cycle Assessment, Marketing Strategy, Market Study, and IP Strategy.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Selected for first batch of Circular Economy Accelerator in Wuppertal and NRW region. Program includes intensive workshops and corporate conversations to implement circular technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founding partner of b.fab GmbH in February 2018 along with Dr. Frank Kensy and Dr. Arren Bar-Even.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

LanzaTech uses engineered gas fermentation (acetogenic bacteria) to convert CO/CO2 + H2 into ethanol and other chemicals — the same input chemistry (CO2 + H2 from renewable energy) and same target output (bio-based chemicals and fuels) as b.fab's Formate Bioeconomy platform.

TypeDirect peer
Description

Solar Foods produces Solein, a single-cell protein from CO2, water, and renewable electricity via electrolysis and hydrogen-oxidizing bacteria — directly analogous to b.fab's Sustein in product, feedstock, and aquaculture/food end-market.

TypeDirect peer
Description

Newlight produces Aircarbon, a PHA bioplastic made from CO2 and methane via marine microorganisms — directly comparable to b.fab's biopolymer (PHB) output from CO2 and shared positioning in carbon-negative bioplastics.

TypeDirect peer
Description

Air Protein makes single-cell protein from CO2 and renewable hydrogen using hydrogen-oxidizing bacteria — same CO2-to-protein via electrolysis/bioconversion model and overlapping target end-markets in food and feed.

TypeDirect peer
Description

Avantium develops bio-based chemicals and polymers (notably PEF) from plant-based feedstocks and is a partner in b.fab's ICO2NIC consortium — overlapping focus on renewable building-block chemicals and bioplastics at commercial scale.

TypeBroad incumbent
Description

Genomatica is an established synthetic biology company commercializing bio-based chemicals (e.g., bio-BDO, butylene glycol) via engineered microorganisms — comparable business model of licensing biology-based production routes to chemical manufacturers.

TypeEmerging player
Description

Photanol uses engineered cyanobacteria to convert CO2 into organic acids and specialty chemicals — adjacent CO2-to-chemicals platform via photosynthesis rather than formate, but serving the same CCU customer base.

TypeEmerging player
Description

Calysta/Deep Branch produces FeedKind single-cell protein from natural gas (methane) via gas fermentation for aquaculture and pet food — competing single-cell protein product targeting the same aquaculture feed market as b.fab's Sustein.

TypeEmerging player
Description

KnipBio develops single-cell protein ingredients (KnipBio Meal) from methanol and other feedstocks for aquaculture feed — closely comparable alternative SCP platform addressing the same aquaculture customers as Sustein.

10Cemvita Factory
TypeEmerging player
Description

Cemvita Factory develops CO2 utilization technologies using industrial biotech for chemicals and sustainable aviation fuel — adjacent CCU/biotech platform with overlapping end-markets (SAF, biochemicals) to b.fab's bioproduction portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

b.fab

Industrial Biotechnology / Biomanufacturingbfab.bio

b.fab is a German biotech startup that converts industrial CO2 and renewable electricity into biochemicals via its proprietary Formate Bioeconomy platform, licensing synthetic biology pathways to chemical manufacturers and selling Sustein single cell protein for aquaculture feed.

What b.fab does

b.fab GmbH is a privately-held German biotechnology startup founded in February 2018 by Dr. Frank Kensy, Dr. Arren Bar-Even (deceased 2020) and b.value AG, headquartered in Cologne with origins in Dortmund. The company operates a proprietary Formate Bioeconomy platform that combines electrochemistry with synthetic biology to convert industrial CO2 and renewable electricity into value-added biochemicals. In its first stage, CO2 is electrochemically reduced to formic acid; in the second stage, engineered microbial strains (formatotrophs) using the reductive glycine pathway (rGP) — first demonstrated in vivo in E. coli by co-founder Bar-Even — convert formate into proteins, amino acids, biopolymers, fatty acids and terpenes. The company's technology has been validated in peer-reviewed work, including >3 g/L mevalonate titers from CO2-derived formate published in Nature Communications.

b.fab commercializes its technology through two routes: (1) licensing of synthetic biology pathways in microbial hosts using formic acid or methanol as the sole carbon source, targeted at enterprise chemical and manufacturing customers, and (2) direct product sales of Sustein, a single-cell protein for aquaculture feed launched in 2024 that requires 14x less land than soy protein. The company is embedded in multiple EU-funded research consortia — eforfuel (2018), TRANSFORMATE (BMBF, 2020–2023), and ICO2NIC (€14M, January 2025, 11 partners) — and participates in accelerators including Hatch Blue CREST (2024) and Circular Valley (2021). Its primary customer segments are enterprise chemical manufacturers seeking carbon-negative biomanufacturing inputs and the aquaculture feed industry seeking sustainable protein alternatives.

As of late 2025, b.fab operates with 1–10 employees, has no disclosed revenue, and is preparing for pilot-scale biochemical production in 2026 via its OCOchem partnership. The company is almost entirely grant-funded rather than equity-backed, with key milestones ahead including scaling rGP-based bioproduction and translating Sustein from pilot to commercial aquaculture sales.

b.fab firmographics

Firmographics
Name
b.fab
Legal name
b.fab GmbH
Website
https://bfab.bio
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
b.fab is a German biotech startup that converts industrial CO2 and renewable electricity into biochemicals via its proprietary Formate Bioeconomy platform, licensing synthetic biology pathways to chemical manufacturers and selling Sustein single cell protein for aquaculture feed.
Ownership category
akta.pro rank

b.fab industry classification

Industry
Product category
Industrial Biotechnology / Biomanufacturing
NAICS
Other Basic Organic Chemical Manufacturing (32519)
SIC
Industrial Organic Chemicals (2860)
akta.pro industry
PRIMARYEUAAAIAA
Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • CO2 utilization
  • Synthetic biology
  • Biomanufacturing technology
  • Carbon-negative chemicals
  • Single cell protein

Where b.fab is headquartered

Location

Headquarters

HQ city
Köln
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

b.fab business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Technology Licensing: b.fab licenses its synthetic biology pathways and biomanufacturing technology to manufacturing and chemical industry companies. They offer technology licences for use of synthetic pathways in microbial hosts utilizing formic or methanol as sole carbon source.
  2. Product Sales (Future): Plans to commercialize products including Sustein, a single cell protein made from CO2-based formate for aquaculture feed applications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

b.fab product offering

Product offering

Core offering

b.fab develops and licenses a proprietary Formate Bioeconomy Platform that combines electrochemical CO2 conversion with synthetic biology to produce value-added biochemicals (amino acids, biopolymers, fatty acids, terpenes, proteins) from CO2 and renewable electricity. The company also produces Sustein, a single-cell protein made from CO2-based formate for aquaculture feed, offering it alongside its technology licensing business to manufacturing and chemical industry customers.

Product overview

b.fab is a biotechnology company offering a unified platform combining electrochemistry and synthetic biology to convert CO2 and renewable energy into biochemicals. The core offering is the Formate Bioeconomy Platform, which converts CO2 to formic acid and then uses engineered microbial strains to produce value-added products. The company commercializes its technology through two main routes: (1) direct product sales of Sustein, a single cell protein for aquaculture feed, and (2) technology licensing, offering licences for synthetic pathways in microbial hosts using formic acid or methanol as the sole carbon source. The technology has been demonstrated for amino acids, biopolymers (PHB), fatty acids, terpenes, and proteins. b.fab also engages in collaborative research projects (e.g., ICO2NIC, TRANSFORMATE, eforfuel) to advance and scale its platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Sustain: Single cell protein made from CO2-based formate for aquaculture feed applications. Made from CO2 and renewable electricity using a simple fermentation process requiring minimal land use (14x less than soy protein).

Products and services

  • Sustein Sustein is a single-cell protein produced from CO2-based formate via a simple fermentation process using engineered microbial strains. It serves as a sustainable protein ingredient for aquaculture feed applications and requires 14x less land than conventional soy protein.
  • Technology Licence for Synthetic Pathway in Microbial Hosts Utilizing Formic or Methanol as Sole Carbon Source b.fab offers technology licensing for synthetic biology pathways in microbial hosts that use formic acid or methanol as the sole carbon source. The technology has been demonstrated for amino acids, biopolymers, fatty acids, terpenes, and proteins, and can be tuned to customer-specific needs for chemical industry and manufacturing partners.

Quantifiable outcome

  • Sustein requires 14x less land than soy protein
  • +1 more outcomes

Companies that use b.fab

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

b.fab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

b.fab partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and minor.

  • OCOchemcoreStrategic or Co-development Partner · 18 December 2025Partnership to accelerate production of biochemicals using OCOchem's sustainably made CO2-based formate. OCOchem has developed gas diffusion electrodes achieving 100x greater CO2 conversion, room temperature/pressure operation, and 35%+ formate concentration. Collaboration enables b.fab to scale technology using fossil-free formate and close the industrial CO2 circle. Small pilot scale production starting 2026.
  • ICO2NIC ConsortiumcoreStrategic or Co-development Partner · 1 January 2025EU-funded project with €14 million in funding. 11 partners across CCU value chain including SINTEF, Avantium, Tüpraş, Cool Planet Technologies, Procter & Gamble, Idener, Nopalm Ingredients, Bio Base Europe Pilot Plant, TNO, and CO2 Value Europe. b.fab will scale up bioprocess for protein production and demonstrate value chain from industrial CO2 emitter to feed customers over 4 years starting January 2025.
  • TRANSFORMATE Project PartnersmajorStrategic or Co-development PartnerBMBF-funded project (01.03.2020 to 28.02.2023) with 7 partners: Max Planck Institute for Molecular Plant Physiology, Max Planck Institute for Colloids and Interfaces, University Stuttgart, Ertel IonStream UG, YNCORIS GmbH & Co. KG, and Dechema e.V. Goal: convert CO2 from industrial parks into biopolymers (PHB and crotonic acid) using electrochemical conversion and biotechnology.
  • eforfuel Project ConsortiummajorStrategic or Co-development Partner4-year European project starting March 2018 coordinated by co-founder Arren Bar-Even. Goal: De novo metabolic conversion of electrochemically produced formate into hydrocarbon fuels.
  • Hatch Blue (CREST Accelerator)majorGTM or Marketing PartnerWorld-leading aquaculture accelerator program. b.fab selected for intensive 4-month program across Hawai'i, Norway, Singapore and Vietnam to access global aquaculture industry, receive mentorship, and develop business plan with deliverables including Life Cycle Assessment, Marketing Strategy, Market Study, and IP Strategy.
  • Circular Valley (Circular Economy Accelerator)minorGTM or Marketing PartnerSelected for first batch of Circular Economy Accelerator in Wuppertal and NRW region. Program includes intensive workshops and corporate conversations to implement circular technology.
  • b.value AGcoreStrategic or Co-development PartnerCo-founding partner of b.fab GmbH in February 2018 along with Dr. Frank Kensy and Dr. Arren Bar-Even.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

b.fab competitors and assessment

Company assessment

Direct peers

  • LanzaTech: LanzaTech uses engineered gas fermentation (acetogenic bacteria) to convert CO/CO2 + H2 into ethanol and other chemicals — the same input chemistry (CO2 + H2 from renewable energy) and same target output (bio-based chemicals and fuels) as b.fab's Formate Bioeconomy platform.
  • Solar Foods: Solar Foods produces Solein, a single-cell protein from CO2, water, and renewable electricity via electrolysis and hydrogen-oxidizing bacteria — directly analogous to b.fab's Sustein in product, feedstock, and aquaculture/food end-market.
  • Newlight Technologies: Newlight produces Aircarbon, a PHA bioplastic made from CO2 and methane via marine microorganisms — directly comparable to b.fab's biopolymer (PHB) output from CO2 and shared positioning in carbon-negative bioplastics.
  • Air Protein: Air Protein makes single-cell protein from CO2 and renewable hydrogen using hydrogen-oxidizing bacteria — same CO2-to-protein via electrolysis/bioconversion model and overlapping target end-markets in food and feed.
  • Avantium: Avantium develops bio-based chemicals and polymers (notably PEF) from plant-based feedstocks and is a partner in b.fab's ICO2NIC consortium — overlapping focus on renewable building-block chemicals and bioplastics at commercial scale.

Broad incumbents

  • Genomatica: Genomatica is an established synthetic biology company commercializing bio-based chemicals (e.g., bio-BDO, butylene glycol) via engineered microorganisms — comparable business model of licensing biology-based production routes to chemical manufacturers.

Emerging players

  • Photanol: Photanol uses engineered cyanobacteria to convert CO2 into organic acids and specialty chemicals — adjacent CO2-to-chemicals platform via photosynthesis rather than formate, but serving the same CCU customer base.
  • Calysta (now part of Deep Branch Biotechnology): Calysta/Deep Branch produces FeedKind single-cell protein from natural gas (methane) via gas fermentation for aquaculture and pet food — competing single-cell protein product targeting the same aquaculture feed market as b.fab's Sustein.
  • KnipBio: KnipBio develops single-cell protein ingredients (KnipBio Meal) from methanol and other feedstocks for aquaculture feed — closely comparable alternative SCP platform addressing the same aquaculture customers as Sustein.
  • Cemvita Factory: Cemvita Factory develops CO2 utilization technologies using industrial biotech for chemicals and sustainable aviation fuel — adjacent CCU/biotech platform with overlapping end-markets (SAF, biochemicals) to b.fab's bioproduction portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

b.fab social profiles

Digital presence

b.fab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

b.fab leadership team

Management profile

Number of profiles

Profiles4 records

b.fab funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

b.fab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about b.fab

What does b.fab do?

b.fab develops and licenses a proprietary Formate Bioeconomy Platform that combines electrochemical CO2 conversion with synthetic biology to produce value-added biochemicals (amino acids, biopolymers, fatty acids, terpenes, proteins) from CO2 and renewable electricity. The company also produces Sustein, a single-cell protein made from CO2-based formate for aquaculture feed, offering it alongside its technology licensing business to manufacturing and chemical industry customers.

Is b.fab a public or private company?

b.fab is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was b.fab founded?

b.fab was founded in 2018. It employs 1 to 10 people.

Where is b.fab based?

b.fab is headquartered in Köln, Germany, in the Europe region.

How does b.fab make money?

Two revenue lines are on record. Technology Licensing is the primary driver. The others are product Sales (Future).

Who are b.fab's main competitors?

Direct peers on record are LanzaTech, Solar Foods, Newlight Technologies, Air Protein and Avantium. Genomatica is listed as a broad incumbent. Emerging players are Photanol, Calysta (now part of Deep Branch Biotechnology), KnipBio and Cemvita Factory.

Does b.fab have an API?

No public API is recorded for b.fab.

What industry is b.fab in?

b.fab's product category is Industrial Biotechnology / Biomanufacturing. Its primary akta.pro industry code is EUAAAIAA, Bio-based Platform & Commodity Chemicals (e.g., bio-ethylene, bio-propylene, bio-BTX, bio-methanol). Its NAICS code is 32519 and its SIC code is 2860.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals